Covid-19 Outpatient Trial Shows 'Significantly Reduced' Virus Levels With Antibody Cocktail

Sarasota Memorial Hospital is currently participating in two trials using the Regeneron Pharmaceuticals drugs.

By Staff November 4, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) this week announced positive, prospective results from an ongoing Covid-19 Phase 2/3 outpatient trial. The results show that Regeneron's investigational antibody cocktail, REGN-COV2, met primary and key secondary endpoints, significantly reducing viral load and patient medical visits (which include hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). You can read the full report here.

Sarasota Memorial Hospital is currently enrolling patients in Regeneron's REGN-Cov-2 trial for preventing Covid-19 in healthy adults, as well as its study of the REGN-CoV-2 antibody cocktail for treating COVID-19 in hospitalized and non-hospitalized adults. For more information, click here.

Filed under
Show Comments